), and the Cochrane Library through Wiley (ending December 15, 2017). Key findings: Of 160 patients with carotid webs, 135 (84%) were symptomatic and 24 (15%) were asymptomatic (1 could not be classified). Twenty-six patients (22%) had bilateral carotid webs. Regarding symptomatic patients, the median age was 46 years, 70% were black, 67% were women, and the majority (84%) had <50% internal carotid artery stenosis. Forty-seven (28%) symptomatic patients were managed medically (91% with antiplatelet agents); more than half of these patients (56%) suffered recurrent strokes distal to the carotid web during follow-up (median, 12 months; range, 0-97 months). Treatment of the other 70 (72%) symptomatic patients was equally divided between carotid endarterectomy and carotid stenting (CAS), and there were no complications.
The law of natural selection: Complex open aortic aneurysm repairs will more commonly be performed at high-volume centersdwithout the need for regulation (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and high (>14) volumes of cases had adjusted perioperative mortality of 9%, 5%, and 4%, respectively (P <.01). High-volume centers were more likely to use renal protective devices such as cold renal perfusion. Twenty-two centers (13%) stopped performing open JR-AAA repairs during this 13-year period.
Conclusion: Complex open AAA repairs should be performed at experienced centers, and future efforts should focus on centralization of complex aortic care.
Commentary: I am unsure whether I fully agree with the concept of centralized care for major vascular operations, but instead results need to be analyzed on a hospital-by-hospital basis. If a low-or medium-volume hospital consistently demonstrates results as good as those of a high-volume center, how can an individual or governing body instruct the vascular surgeons operating at that hospital to refer patients elsewhere? We also need to consider vascular training programs if we endorse this policy of centralization. We hear more and more about the future potential shortage of vascular surgeons, but if we diminish the number of training programs by centralizing cases, what trainee will want to go to a hospital where the vascular surgeons refer complex aortic cases elsewhere? Such a policy will certainly result in fewer training programs, unless the fellows at the low-volume hospitals are shipped out for months at a time to the high-volume hospitals. But we all agree we must do what is best for our patients.
This study illustrated that natural selection may play a role in centralization. More than 10% of low-volume hospitals in this review stopped doing open JR-AAA repairs during this time period (although the authors point out that some continued to do a low volume of cases). This result occurred not because the surgeons were ordered to send their patients to a higher volume hospital but more likely because the surgeons at the low-volume hospitals did not feel comfortable doing these rare cases anymore, or even more likely, patients with complex aortic aneurysms were not being referred to the low-volume hospital anymore. Word gets around.
Quick summary of antiplatelet agents for vascular surgeons: (1) give aspirin or clopidogrel for symptomatic patients with lower extremity arterial disease and carotid stenosis and after arterial surgery and (2) give both after endovascular interventions Antiplatelet Therapy for Peripheral Artery Disease Melfi R, Ricottini E. Cardiovasc Diagn Ther 2018;8:663-77.
Study design: A review was conducted of registries, randomized trials, and meta-analysis publications from PubMed between 1994 and 2018 and on-line clinical trials in 2018.
Key findings: For patients with lower extremity arterial disease, recommendations include the following: asymptomatic, no antiplatelet agents (especially diabetics) vs aspirin or clopidogrel alone; symptomatic patients and postsurgical intervention, aspirin or clopidogrel alone; after endovascular intervention, both for 1 month.
For patients with carotid stenosis, recommendations include the following: asymptomatic >50% stenosis, aspirin alone; symptomatic patients, aspirin or clopidogrel alone (although some studies showed that dual treatment is better); postsurgical intervention, aspirin or clopidogrel alone (clopidogrel may slightly decrease the perioperative stroke rate but may slightly increase the bleeding rate); after endovascular intervention, dual treatment for 1 month.
The authors also concluded that there is no significant relative risk reduction for cardiovascular death, myocardial infarction, or stroke with different doses of aspirin vs placebo for lower extremity arterial disease. Some studies of lower extremity occlusive disease have suggested that ticagrelor, a reversible P2Y 12 antagonist, may be more beneficial than clopidogrel, but this remains controversial. Oral anticoagulants are not beneficial for prevention of neurologic events due to carotid stenosis.
Conclusion: The greatest evidence showing the benefit of antiplatelet agents in reducing cardiovascular events is from large trials of coronary artery disease.
Commentary: It is very difficult to summarize the vast literature on this topic. The preceding comments are a brief summary of the authors' findings. For the interested reader, the article provides an in-depth summary of antiplatelet treatment of lower extremity arterial disease and carotid stenosis.
Will common femoral endarterectomy be of only historic interest in the future? Approximately one-third of CFA lesions that were initially treated with balloon angioplasty required provisional stenting as a bailout procedure. Four studies employed primary stenting to treat isolated CFA disease, with 1-year primary patency of about 85%; one study reported a 5-year primary patency of 73%. The authors note that short, single selfexpanding stents such as the Supera (Abbott Vascular, Santa Clara, Calif) may be less susceptible to fracture when used in this location. They also suggest that adjunctive atherectomy may be useful to debulk heavily calcified diffuse plaque, noting that one study reported a 4-year primary patency rate of 87% when atherectomy was used alone. Other studies showed improved patency of atherectomy and balloon angioplasty compared with balloon angioplasty alone.
Conclusion: Endovascular therapy for CFA atherosclerotic lesions provides acceptable short-term technical outcomes with few periprocedural complications.
Commentary: Atherosclerotic lesions of the CFA can be extensively eccentric and calcified, which vascular surgeons believe limits the effectiveness of endovascular approaches. Concerns of endovascular intervention to treat CFA lesions
